Pretty emotive post.......and not accurate IMHO.
Much depends if you are short term or long term for this stock.
(Disc - holding long term and up 340% to date..... so DYOR )
Printable View
Had someone post on an Investor page "Plexure confirm timeline of joining ASX September/October via Notice of meeting letter.
Does anyone know anything about this?
"Should the Company decide to proceed with the IPO, it is expected that any IPO offer will open in late September/early October with the ASX listing (and NZX secondary listing) in place by late October/early November. However, this timeline remains indicative and is subject to a number of factors including the regulatory approvals noted above and market conditions. An announcement will be made to the market if Plexure decides to proceed with the IPO and ASX Listing and NZX secondary listing."
In the Notice of Meeting letter, the announcement dated 18/8/2020.
Mainfreight isn’t dual listed and it doesn’t seem to have done their share price any harm.
I think New Zealand has a tendency to undervalue biotech companies because it’s not something that New Zealand investors or analysts understand as well as Australian investors. However, I think that by and large, the New Zealand investing community and the analysts working for the institutions understand software companies and marketing as well as the Australian market. Any big increase in customers is going to lift the price, whether it is listed on the NZX or the ASX.
I think it’s a shame when we always assume that Australians do things bigger and better than Kiwis.
At the end of the day I support whatever helps the company grow and helps to return the greatest value to shareholders.
I also support New Zealand shareholders not only getting a preferential allocation but being able to take up as much as they want and then leaving the balance for Australian shareholders and institutions to fight over. I don’t feel that existing shareholders should be “rationed” to a small pool of shares to fight over